Role of GB virus C in modulating HIV disease

References

• Simons JN, Pilot-Matias TJ, Leary TP et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl Acad. Sci. USA 92(8), 3401–3405 (1995).
   PubMed Web of Science ®Google Scholar
• Simons JN, Leary TP, Dawson GJ et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat. Med. 1(6), 564–569 (1995).
   PubMed Web of Science ®Google Scholar
• Linnen J, Wages J Jr, Zhang-Keck ZY et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271(5248), 505–508 (1996).
   PubMed Web of Science ®Google Scholar
• Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N. Engl. J. Med. 334(23), 1536–1537 (1996).
   PubMed Web of Science ®Google Scholar
• Leary TP, Muerhoff AS, Simons JN et al. Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A–E hepatitis. J. Med. Virol. 48(1), 60–67 (1996).
   PubMed Web of Science ®Google Scholar
• Baggio-Zappia GL, Hernandes Granato CF. HIV-GB virus C co-infection: an overview. Clin. Chem. Lab. Med. 47(1), 12–19 (2009).
   PubMed Web of Science ®Google Scholar
• Nerurkar VR, Chua PK, Hoffmann PR, Dashwood WM, Shikuma CM, Yanagihara R. High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. J. Med. Virol. 56(2), 123–127 (1998).
   PubMed Web of Science ®Google Scholar
• Scallan MF, Clutterbuck D, Jarvis LM, Scott GR, Simmonds P. Sexual transmission of GB virus C/hepatitis G virus. J. Med. Virol. 55(3), 203–208 (1998).
   PubMed Web of Science ®Google Scholar
• Bourlet T, Guglielminotti C, Evrard M et al. Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. J. Med. Virol. 58(4), 373–377 (1999).
   PubMed Web of Science ®Google Scholar
• Woelfle J, Berg T, Keller KM, Schreier E, Lentze MJ. Persistent hepatitis G virus infection after neonatal transfusion. J. Pediatr. Gastroenterol. Nutr. 26(4), 402–407 (1998).
   PubMed Web of Science ®Google Scholar
• Jarvis LM, Davidson F, Hanley JP, Yap PL, Ludlam CA, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 348(9038), 1352–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Fischler B, Lara C, Chen M, Sönnerborg A, Nemeth A, Sällberg M. Genetic evidence for mother-to-infant transmission of hepatitis G virus. J. Infect. Dis. 176(1), 281–285 (1997).
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Tanzi E, Romanó L et al. Multicenter trial on mother-to-infant transmission of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses Transmission. J. Med. Virol. 54(2), 107–112 (1998).
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Smuts HE. Review of the epidemiology, molecular characterization and tropism of the hepatitis G virus/GBV-C. Clin. Lab. 47(5-6), 239–248 (2001).
   PubMedGoogle Scholar
• Dawson GJ, Schlauder GG, Pilot-Matias TJ et al. Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J. Med. Virol. 50(1), 97–103 (1996).
   PubMed Web of Science ®Google Scholar
• Hyland CA, Mison L, Solomon N et al. Exposure to GB virus type C or hepatitis G virus in selected Australian adult and children populations. Transfusion 38(9), 821–827 (1998).
   PubMed Web of Science ®Google Scholar
• Blair CS, Davidson F, Lycett C et al. Prevalence, incidence, and clinical characteristics of hepatitis G virus/GB virus C infection in Scottish blood donors. J. Infect. Dis. 178(6), 1779–1782 (1998).
   PubMed Web of Science ®Google Scholar
• El-Zayadi AR, Abe K, Selim O, Naito H, Hess G, Ahdy A. Prevalence of GBV-C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. J. Virol. Methods 80(1), 53–58 (1999).
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Louw SJ, Robson SC, Isaacs S, Kirsch RE. High prevalence of GBV-C hepatitis G virus infection in a rural South African population. J. Med. Virol. 53(3), 225–228 (1997).
   PubMed Web of Science ®Google Scholar
• Ren FR, Wang Y, Li H, Chen HS, Zhao HY. Hepatitis G virus infection in screened Chinese blood donors. Vox Sang. 74(1), 51–52 (1998).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Mizokami M, Orito E et al. GB virus C/hepatitis G virus infection among Colombian native Indians. Am. J. Trop. Med. Hyg. 59(3), 462–467 (1998).
   PubMed Web of Science ®Google Scholar
• Bassit L, Kleter B, Ribeiro-dos-Santos G et al. Hepatitis G virus: prevalence and sequence analysis in blood donors of São Paulo, Brazil. Vox Sang. 74(2), 83–87 (1998).
   PubMed Web of Science ®Google Scholar
• Masuko K, Mitsui T, Iwano K et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N. Engl. J. Med. 334(23), 1485–1490 (1996).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Nakatsuji Y, Shih JW et al. Persistence and clinical significance of hepatitis G virus infections in injecting drug users. J. Infect. Dis. 176(3), 586–592 (1997).
   PubMedGoogle Scholar
• Stark K, Bienzle U, Hess G, Engel AM, Hegenscheid B, Schluter V. Detection of the hepatitis G virus genome among injecting drug users, homosexual and bisexual men, and blood donors. J. Infect. Dis. 174(6), 1320–1323 (1996).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Vlahov D, Alter HJ et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J. Infect. Dis. 177(3), 539–542 (1998).
   PubMedGoogle Scholar
• Tillmann HL, Heringlake S, Trautwein C et al. Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology 28(2), 379–384 (1998).
   PubMed Web of Science ®Google Scholar
• Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety. Transfus. Med. Rev. 15(3), 201–212 (2001).
   PubMedGoogle Scholar
• Pilot-Matias TJ, Carrick RJ, Coleman PF et al. Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 225(2), 282–292 (1996).
   PubMedGoogle Scholar
• Tanaka E, Tacke M, Kobayashi M et al. Past and present hepatitis G virus infections in areas where hepatitis C is highly endemic and those where it is not endemic. J. Clin. Microbiol. 36(1), 110–114 (1998).
   PubMedGoogle Scholar
• Tacke M, Schmolke S, Schlueter V et al. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 26(6), 1626–1633 (1997).
   PubMed Web of Science ®Google Scholar
• Stapleton JT. GB virus type C/Hepatitis G virus. Semin. Liver Dis. 23(2), 137–148 (2003).
   PubMed Web of Science ®Google Scholar
• Williams CF, Klinzman D, Yamashita TE et al. Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. 350(10), 981–990 (2004).
   PubMed Web of Science ®Google Scholar
• Van der Bij AK, Kloosterboer N, Prins M et al. GB virus C co-infection and HIV-1 disease progression: the Amsterdam Cohort Study. J. Infect. Dis. 191(5), 678–685 (2005).
   PubMedGoogle Scholar
• Björkman P, Flamholc L, Widell A. GB virus C and survival in persons with HIV infection. N. Engl. J. Med. 350(25), 2617–2618; author reply 2617 (2004).
   PubMedGoogle Scholar
• Xiang J, Wünschmann S, Schmidt W, Shao J, Stapleton JT. Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J. Virol. 74(19), 9125–9133 (2000).
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Manns MP. GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res. 52(2), 83–90 (2001).
   PubMed Web of Science ®Google Scholar
• Sauleda S, Reesink HJ, Esteban JI, Hess G, Esteban R, Guardia J. Profiles of GBV-C/hepatitis G virus markers in patients coinfected with hepatitis C virus. J. Med. Virol. 59(1), 45–51 (1999).
   PubMedGoogle Scholar
• Ruiz V, Espínola L, Mathet VL, Perandones CE, Oubiña JR. Design, development and evaluation of a competitive RT-PCR for quantitation of GBV-C RNA. J. Virol. Methods 136(1–2), 58–64 (2006).
   PubMedGoogle Scholar
• Gómara MJ, Fernández L, Pérez T, Ercilla G, Haro I. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection. Anal. Biochem. 396(1), 51–58 (2010).
   PubMed Web of Science ®Google Scholar
• Gómara MJ, Fernández L, Pérez T et al. Diagnostic value of anti-GBV-C antibodies in HIV-infected patients. Chem. Biol. Drug Des. 78(2), 277–282 (2011).
   PubMedGoogle Scholar
• Mohr EL, Stapleton JT. GB virus type C interactions with HIV: the role of envelope glycoproteins. J. Viral Hepat. 16(11), 757–768 (2009).
   PubMed Web of Science ®Google Scholar
• Polgreen PM, Xiang J, Chang Q, Stapleton JT. GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microbes Infect. 5(13), 1255–1261 (2003).
   PubMedGoogle Scholar
• Belyaev AS, Chong S, Novikov A et al. Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins. J. Virol. 72(1), 868–872 (1998).
   PubMed Web of Science ®Google Scholar
• Saito S, Tanaka K, Kondo M et al. Plus- and minus-stranded hepatitis G virus RNA in liver tissue and in peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 237(2), 288–291 (1997).
   PubMedGoogle Scholar
• Sergi C, Jundt K, Seipp S et al. The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. J. Hepatol. 29(6), 861–871 (1998).
   PubMedGoogle Scholar
• Seipp S, Scheidel M, Hofmann WJ et al. Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell lines. J. Hepatol. 30(4), 570–579 (1999).
   PubMedGoogle Scholar
• Cao MM, Ren H, Zhao P, Pan W, Chen QL, Qi ZT. Persistent replication of the GBV-C subgenomic replicons in Huh7 cells. J. Virol. Methods 157(2), 168–174 (2009).
   PubMedGoogle Scholar
• Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses. J. Virol. 71(10), 7804–7806 (1997).
   PubMed Web of Science ®Google Scholar
• Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J. Gen. Virol. 79(Pt 4), 705–714 (1998).
   PubMedGoogle Scholar
• Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Detection of hepatitis G virus replication sites by using highly strand-specific Tth-based reverse transcriptase PCR. J. Virol. 72(4), 3072–3075 (1998).
   PubMed Web of Science ®Google Scholar
• Radkowski M, Kubicka J, Kisiel E et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 95(12), 3986–3989 (2000).
   PubMed Web of Science ®Google Scholar
• George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. J. Infect. Dis. 193(3), 451–454 (2006).
   PubMed Web of Science ®Google Scholar
• Handa A, Brown KE. GB virus C/hepatitis G virus replicates in human haematopoietic cells and vascular endothelial cells. J. Gen. Virol. 81(Pt 10), 2461–2469 (2000).
   PubMedGoogle Scholar
• Tucker TJ, Smuts HE, Eedes C et al. Evidence that the GBV-C/hepatitis G virus is primarily a lymphotropic virus. J. Med. Virol. 61(1), 52–58 (2000).
   PubMed Web of Science ®Google Scholar
• Thiel H-J, Collett MS, Gould EA et al. Virus Taxonomy: Eighth Report of the International Committee on Taxonomy Of Viruses. Elsevier Academic Press, London, UK (2005).
   Google Scholar
• Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J. Gen. Virol. 92(Pt 2), 233–246 (2011).
   PubMed Web of Science ®Google Scholar
• Muerhoff AS, Dawson GJ, Desai SM. A previously unrecognized sixth genotype of GB virus C revealed by analysis of 5´ untranslated region sequences. J. Med. Virol. 78(1), 105–111 (2006).
   PubMedGoogle Scholar
• Smith DB, Basaras M, Frost S et al. Phylogenetic analysis of GBV-C/hepatitis G virus. J. Gen. Virol. 81(Pt 3), 769–780 (2000).
   PubMedGoogle Scholar
• Naito H, Abe K. Genotyping system of GBV-C/HGV type 1 to type 4 by the polymerase chain reaction using type-specific primers and geographical distribution of viral genotypes. J. Virol. Methods 91(1), 3–9 (2001).
   PubMed Web of Science ®Google Scholar
• Muerhoff AS, Simons JN, Erker JC, Desai SM, Mushahwar IK. Identification of conserved nucleotide sequences within the GB virus C 5´ untranslated region: design of PCR primers for detection of viral RNA. J. Virol. Methods 62(1), 55–62 (1996).
   PubMedGoogle Scholar
• Smith DB, Cuceanu N, Davidson F et al. Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5´ non-coding region. J. Gen. Virol. 78(Pt 7), 1533–1542 (1997).
   PubMedGoogle Scholar
• Liu HF, Muyembe-Tamfum JJ, Dahan K, Desmyter J, Goubau P. High prevalence of GB virus C/hepatitis G virus in Kinshasa, Democratic Republic of Congo: a phylogenetic analysis. J. Med. Virol. 60(2), 159–165 (2000).
   PubMedGoogle Scholar
• Tucker TJ, Smuts H, Eickhaus P, Robson SC, Kirsch RE. Molecular characterization of the 5´ non-coding region of South African GBV-C/HGV isolates: major deletion and evidence for a fourth genotype. J. Med. Virol. 59(1), 52–59 (1999).
   PubMedGoogle Scholar
• Tucker TJ, Smuts HE. GBV-C/HGV genotypes: proposed nomenclature for genotypes 1-5. J. Med. Virol. 62(1), 82–83 (2000).
   PubMedGoogle Scholar
• Nishiya AS, Ribeiro-dos-Santos G, Bassit L, Focaccia R, Chamone DF, Sabino EC. Genotype distribution of the GB virus C in citizens of São Paulo City, Brazil. Rev. Inst. Med. Trop. Sao Paulo 45(4), 213–216 (2003).
   PubMedGoogle Scholar
• Alcalde R, Nishiya A, Casseb J, Inocêncio L, Fonseca LA, Duarte AJ. Prevalence and distribution of the GBV-C/HGV among HIV-1-infected patients under anti-retroviral therapy. Virus Res. 151(2), 148–152 (2010).
   PubMed Web of Science ®Google Scholar
• Muerhoff AS, Leary TP, Sathar MA, Dawson GJ, Desai SM. African origin of GB virus C determined by phylogenetic analysis of a complete genotype 5 genome from South Africa. J. Gen. Virol. 86(Pt 6), 1729–1735 (2005).
   PubMedGoogle Scholar
• Branco C, Esteves A, Piedade J, Parreira R. A new genotype 2 subcluster identified among GBV-C strains circulating in the Lisbon metropolitan area of Portugal. J. Med. Virol. 82(3), 452–459 (2010).
   PubMedGoogle Scholar
• Liu HF, Teng CW, Fukuda Y et al. A novel subtype of GB virus C/hepatitis G virus genotype 1 detected uniquely in patients with hemophilia in Japan. J. Med. Virol. 71(3), 385–390 (2003).
   PubMedGoogle Scholar
• Neibecker M, Schwarze-Zander C, Rockstroh JK, Spengler U, Blackard JT. Evidence for extensive genotypic diversity and recombination of GB virus C (GBV-C) in Germany. J. Med. Virol. 83(4), 685–694 (2011).
   PubMed Web of Science ®Google Scholar
• Worobey M, Holmes EC. Homologous recombination in GB virus C/hepatitis G virus. Mol. Biol. Evol. 18(2), 254–261 (2001).
   PubMedGoogle Scholar
• Fan X, Xu Y, Detre K, Di Bisceglie AM. Direct evidence for GB virus C/hepatitis G virus (GBV-C/HGV) superinfection: elimination of resident viral strain by donor strain in a patient undergoing liver transplantation. J. Med. Virol. 68(1), 76–81 (2002).
   PubMedGoogle Scholar
• García F Jr, García F, Bernal MC, Piédrola G, Maroto MC. Genomic variability of hepatitis G virus/GBV-C at the NS3 region: clinical implications. Microbios 102(401), 17–25 (2000).
   PubMedGoogle Scholar
• Zampino R, Pickering J, Iqbal M, Gaud U, Thomas HC, Karayiannis P. Hepatitis G virus/GBV-C persistence: absence of hypervariable E2 region and genetic analysis of viral quasispecies in serum and lymphocytes. J. Viral Hepat. 6(3), 209–218 (1999).
   PubMedGoogle Scholar
• Ruiz V, Giordano M, Rivero CW et al. GB virus C quasispecies detected in plasma and lymphocyte subsets in a natural human infection. J. Gen. Virol. 91(Pt 7), 1687–1692 (2010).
   PubMedGoogle Scholar
• Kato T, Mizokami M, Nakano T et al. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus. J. Med. Virol. 55(2), 109–117 (1998).
   PubMedGoogle Scholar
• Shimizu YK, Hijikata M, Kiyohara T, Kitamura Y, Yoshikura H. Replication of GB virus C (hepatitis G virus) in interferon-resistant Daudi cells. J. Virol. 73(10), 8411–8414 (1999).
   PubMedGoogle Scholar
• Fogeda M, López-Alcorocho JM, Bartolomé J, Arocena C, Martín MA, Carreño V. Existence of distinct GB virus C/hepatitis G virus variants with different tropism. J. Virol. 74(17), 7936–7942 (2000).
   PubMedGoogle Scholar
• Xiang J, Martinez-Smith C, Gale M Jr et al. GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2alpha phosphorylation. J. Interferon Cytokine Res. 25(5), 261–270 (2005).
   PubMedGoogle Scholar
• George SL, Xiang J, Stapleton JT. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 316(2), 191–201 (2003).
   PubMed Web of Science ®Google Scholar
• Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin. Infect. Dis. 34(8), 1108–1114 (2002).
   PubMed Web of Science ®Google Scholar
• Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus C/hepatitis G virus co-infection on the course of HIV infection in hemophilia patients in Japan. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17(3), 209–213 (1998).
   PubMedGoogle Scholar
• Heringlake S, Ockenga J, Tillmann HL et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J. Infect. Dis. 177(6), 1723–1726 (1998).
   PubMed Web of Science ®Google Scholar
• Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J. Infect. Dis. 179(4), 783–789 (1999).
   PubMed Web of Science ®Google Scholar
• Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann. Intern. Med. 132(12), 959–963 (2000).
   PubMedGoogle Scholar
• Xiang J, Wünschmann S, Diekema DJ et al. Effect of co-infection with GB virus C on survival among patients with HIV infection. N. Engl. J. Med. 345(10), 707–714 (2001).
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Heiken H, Knapik-Botor A et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345(10), 715–724 (2001).
   PubMed Web of Science ®Google Scholar
• Björkman P, Flamholc L, Molnegren V, Marshall A, Güner N, Widell A. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. AIDS 21(12), 1641–1643 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez B, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H. Effect of GB virus C co-infection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J. Infect. Dis. 187(3), 504–507 (2003).
   PubMedGoogle Scholar
• Mosam A, Sathar MA, Dawood H, Cassol E, Esterhuizen TM, Coovadia HM. Effect of GB virus C co-infection on response to generic HAART in African patients with HIV-1 clade C infection. AIDS 21(10), 1377–1379 (2007).
   PubMed Web of Science ®Google Scholar
• Antonucci G, Girardi E, Cozzi-Lepri A et al.; HepaICoNA Study GroupICoNA Study Group; Response to HAART and GB virus type C co-infection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir. Ther. (Lond.) 10(1), 109–117 (2005).
   PubMedGoogle Scholar
• Tillmann HL, Manns MP, Claes C, Heiken H, Schmidt RE, Stoll M. GB virus C infection and quality of life in HIV-positive patients. AIDS Care 16(6), 736–743 (2004).
   PubMed Web of Science ®Google Scholar
• Birk M, Lindbäck S, Lidman C. No influence of GB virus C replication on the prognosis in a cohort of HIV-1-infected patients. AIDS 16(18), 2482–2485 (2002).
   PubMed Web of Science ®Google Scholar
• Björkman P, Flamholc L, Nauclér A, Molnegren V, Wallmark E, Widell A. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 18(6), 877–886 (2004).
   PubMed Web of Science ®Google Scholar
• Muerhoff AS, Tillmann HL, Manns MP, Dawson GJ, Desai SM. GB virus C genotype determination in GB virus-C/HIV co-infected individuals. J. Med. Virol. 70(1), 141–149 (2003).
   PubMedGoogle Scholar
• Schwarze-Zander C, Blackard JT, Zheng H et al.; AIDS Clinical Trial Group A5071 Study Team. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J. Infect. Dis. 194(4), 410–419 (2006).
   PubMed Web of Science ®Google Scholar
• Berzsenyi MD, Bowden DS, Roberts SK, Revill PA. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease. J. Gastroenterol. Hepatol. 24(8), 1407–1410 (2009).
   PubMedGoogle Scholar
• Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med. 7(3), 173–180 (2006).
   PubMed Web of Science ®Google Scholar
• Yu ML, Chuang WL, Dai CY et al. GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-alpha therapy. Antiviral Res. 52(3), 241–249 (2001).
   PubMedGoogle Scholar
• Oshita M, Hayashi N, Mita E et al. GBV-C/HGV infection in chronic hepatitis C patients: its effect on clinical features and interferon therapy. J. Med. Virol. 55(2), 98–102 (1998).
   PubMedGoogle Scholar
• Pereira LM, Spinelli V, Ximenes RA et al. Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV co-infection on the severity of the disease in a Brazilian population. J. Med. Virol. 67(1), 27–32 (2002).
   PubMedGoogle Scholar
• Pawlotsky JM, Roudot-Thoraval F, Muerhoff AS et al. GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy. J. Med. Virol. 54(1), 26–37 (1998).
   PubMed Web of Science ®Google Scholar
• Boodram B, Hershow RC, Klinzman D, Stapleton JT. GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. J. Viral Hepat. 18(4), e153–e159 (2011).
   PubMedGoogle Scholar
• Manolakopoulos S, Morris A, Davies S, Brown D, Hajat S, Dusheiko G. Influence of GB virus C viraemia on the clinical, virological and histological features of early hepatitis C-related hepatic disease. J. Hepatol. 28(2), 173–178 (1998).
   PubMedGoogle Scholar
• Hofer H, Aydin I, Neumueller-Guber S et al. Prevalence and clinical significance of GB virus type C/hepatitis G virus co-infection in patients with chronic hepatitis C undergoing antiviral therapy. J. Viral Hepat. 18(7), 513–517 (2011).
   PubMed Web of Science ®Google Scholar
• Strauss E, da Costa Gayotto LC, Fay F, Fay O, Fernandes HS, Fischer Chamone Dde A. Liver histology in co-infection of hepatitis C virus (HCV) and hepatitis G virus (HGV). Rev. Inst. Med. Trop. Sao Paulo 44(2), 67–70 (2002).
   PubMedGoogle Scholar
• Yokozaki S, Takamatsu J, Nakano I et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 96(13), 4293–4299 (2000).
   PubMed Web of Science ®Google Scholar
• Tedaldi EM, Baker RK, Moorman AC et al.; HIV Outpatient Study (HOPS) Investigators. Influence of co-infection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 36(3), 363–367 (2003).
   PubMed Web of Science ®Google Scholar
• Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32(3), 492–497 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez-Sierra C, Arizcorreta A, Díaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. 36(4), 491–498 (2003).
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52(7), 1035–1040 (2003).
   PubMed Web of Science ®Google Scholar
• Poynard T, Mathurin P, Lai CL et al.; PANFIBROSIS Group. A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38(3), 257–265 (2003).
   PubMed Web of Science ®Google Scholar
• Soto B, Sánchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 26(1), 1–5 (1997).
   PubMed Web of Science ®Google Scholar
• Lesens O, Deschênes M, Steben M, Bélanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J. Infect. Dis. 179(5), 1254–1258 (1999).
   PubMed Web of Science ®Google Scholar
• Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J. Infect. Dis. 183(7), 1112–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47(6), 845–851 (2000).
   PubMed Web of Science ®Google Scholar
• Puoti M, Bonacini M, Spinetti A et al.; HIV-HCV Co-infection Study Group. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis. 183(1), 134–137 (2001).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30(4), 1054–1058 (1999).
   PubMed Web of Science ®Google Scholar
• Pineda JA, Macías J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J. Antimicrob. Chemother. 55(4), 417–419 (2005).
   PubMedGoogle Scholar
• Shindo M, Arai K, Okuno T. Long-term follow-up of hepatitis G virus/GB virus C replication in liver during and after interferon therapy in patients coinfected with hepatitis C and G viruses. J. Gastroenterol. 34(6), 680–687 (1999).
   PubMedGoogle Scholar
• Kao JH, Lai MY, Chen W, Chen PJ, Chen DS. Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone. J. Gastroenterol. Hepatol. 13(12), 1249–1253 (1998).
   PubMedGoogle Scholar
• Piroth L, Carrat F, Larrat S et al. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J. Hepatol. 49(6), 892–898 (2008).
   PubMedGoogle Scholar
• Shankar EM, Balakrishnan P, Vignesh R, Velu V, Jayakumar P, Solomon S. Current Views on the Pathophysiology of GB Virus C Co-infection with HIV-1 Infection. Curr. Infect. Dis. Rep. 13(1), 47–52 (2011).
   PubMedGoogle Scholar
• Siegal F. Interferon-producing plasmacytoid dendritic cells and the pathogenesis of AIDS. Res. Initiat. Treat. Action 8(2), 10–13 (2003).
   PubMedGoogle Scholar
• Arrode G, Finke JS, Zebroski H, Siegal FP, Steinman RM. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur. J. Immunol. 35(1), 159–170 (2005).
   PubMed Web of Science ®Google Scholar
• Nunnari G, Nigro L, Palermo F et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann. Intern. Med. 139(1), 26–30 (2003).
   PubMed Web of Science ®Google Scholar
• Capobianchi MR, Lalle E, Martini F et al. Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients. Cell. Mol. Biol. (Noisy-le-grand) 52(1), 3–8 (2006).
   PubMedGoogle Scholar
• Lalle E, Sacchi A, Abbate I et al. Activation of interferon response genes and of plasmacytoid dendritic cells in HIV-1 positive subjects with GB virus C co-infection. Int. J. Immunopathol. Pharmacol. 21(1), 161–171 (2008).
   PubMed Web of Science ®Google Scholar
• Meyers JH, Justement JS, Hallahan CW et al. Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2(5), e458 (2007).
   PubMedGoogle Scholar
• Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363(9426), 2040–2046 (2004).
   PubMed Web of Science ®Google Scholar
• Jung S, Knauer O, Donhauser N et al. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS 19(12), 1267–1272 (2005).
   PubMedGoogle Scholar
• Xiang J, McLinden JH, Chang Q, Kaufman TM, Stapleton JT. An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc. Natl Acad. Sci. USA 103(42), 15570–15575 (2006).
   PubMedGoogle Scholar
• Chang Q, McLinden JH, Stapleton JT, Sathar MA, Xiang J. Expression of GB virus C NS5A protein from genotypes 1, 2, 3 and 5 and a 30 aa NS5A fragment inhibit human immunodeficiency virus type 1 replication in a CD4+ T-lymphocyte cell line. J. Gen. Virol. 88(Pt 12), 3341–3346 (2007).
   PubMedGoogle Scholar
• Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS ONE 3(7), e2580 (2008).
   PubMedGoogle Scholar
• Xiang J, McLinden JH, Rydze RA et al. Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J. Immunol. 183(12), 7860–7869 (2009).
   PubMed Web of Science ®Google Scholar
• Nattermann J, Nischalke HD, Kupfer B et al. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17(10), 1457–1462 (2003).
   PubMed Web of Science ®Google Scholar
• Kaufman TM, McLinden JH, Xiang J, Engel AM, Stapleton JT. The GBV-C envelope glycoprotein E2 does not interact specifically with CD81. AIDS 21(8), 1045–1048 (2007).
   PubMedGoogle Scholar
• Schwarze-Zander C, Neibecker M, Othman S et al. GB virus C co-infection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T-cells. Antivir. Ther. (Lond.) 15(5), 745–752 (2010).
   PubMed Web of Science ®Google Scholar
• Jung S, Eichenmüller M, Donhauser N et al. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 21(5), 645–647 (2007).
   PubMedGoogle Scholar
• Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J. Virol. 85(14), 7037–7047 (2011).
   PubMed Web of Science ®Google Scholar
• Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J. Phys. Chem. B 113(20), 7383–7391 (2009).
   PubMed Web of Science ®Google Scholar
• Herrera E, Tenckhoff S, Gómara MJ et al. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. J. Med. Chem. 53(16), 6054–6063 (2010).
   PubMedGoogle Scholar
• Haro I, Gómara MJ, Galatola R et al. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity. Biochim. Biophys. Acta 1808(6), 1567–1573 (2011).
   PubMedGoogle Scholar
• Mohr EL, Xiang J, McLinden JH et al. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J. Immunol. 185(7), 4496–4505 (2010).
   PubMed Web of Science ®Google Scholar
• Hazenberg MD, Stuart JW, Otto SA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95(1), 249–255 (2000).
   PubMed Web of Science ®Google Scholar
• Maidana-Giret MT, Silva TM, Sauer MM et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 23(17), 2277–2287 (2009).
   PubMed Web of Science ®Google Scholar
• Kottilil S, Shin K, Jackson JO et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J. Immunol. 176(2), 1107–1114 (2006).
   PubMedGoogle Scholar
• Silvestris F, Cafforio P, Frassanito MA et al. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. AIDS 10(2), 131–141 (1996).
   PubMed Web of Science ®Google Scholar
• Gougeon ML, Lecoeur H, Sasaki Y. Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Immunol. Lett. 66(1–3), 97–103 (1999).
   PubMedGoogle Scholar
• Moenkemeyer M, Schmidt RE, Wedemeyer H, Tillmann HL, Heiken H. GBV-C co-infection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J. Med. Virol. 80(11), 1933–1940 (2008).
   PubMed Web of Science ®Google Scholar